Get the Stockscreener App
21.16
2.47%
0.51
Genmab Adr stock is traded at $21.16, with a volume of 786.91K.
It is up +2.47% in the last 24 hours and down -8.48% over the past month.
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
See More
Previous Close:
$20.65
Open:
$20.86
24h Volume:
786.91K
Relative Volume:
0.75
Market Cap:
$13.43B
Revenue:
$2.89B
Net Income/Loss:
$684.26M
P/E Ratio:
21.11
EPS:
1.0022
Net Cash Flow:
$958.82M
1W Performance:
+3.47%
1M Performance:
-8.48%
6M Performance:
-24.43%
1Y Performance:
-31.07%
1-Day Range:
$20.84
$21.17
1-Week Range:
$20.34
$21.17
52-Week Range:
$20.34
$32.88
Genmab Adr Stock (GMAB) Company Profile
Compare GMAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GMAB
Genmab Adr
|
21.16 | 13.43B | 2.89B | 684.26M | 958.82M | 1.0022 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-24 | Initiated | Redburn Atlantic | Buy |
| Sep-04-24 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-20-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-15-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-23-24 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-22-24 | Downgrade | Citigroup | Neutral → Sell |
| Dec-06-23 | Upgrade | UBS | Neutral → Buy |
| Nov-10-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Nov-08-23 | Upgrade | DNB Markets | Sell → Buy |
| Oct-18-23 | Initiated | Exane BNP Paribas | Underperform |
| Sep-06-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-24-23 | Initiated | BTIG Research | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-31-23 | Initiated | UBS | Neutral |
| May-12-23 | Initiated | Morgan Stanley | Underweight |
| Dec-20-22 | Downgrade | Citigroup | Buy → Neutral |
| Nov-14-22 | Initiated | William Blair | Mkt Perform |
| Nov-11-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-24-22 | Initiated | BMO Capital Markets | Market Perform |
| May-02-22 | Initiated | Cowen | Market Perform |
| Mar-16-22 | Upgrade | UBS | Neutral → Buy |
| Jan-31-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-01-21 | Initiated | Berenberg | Sell |
| Sep-16-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Aug-24-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-20-21 | Initiated | Deutsche Bank | Buy |
| Jan-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-20 | Downgrade | Bryan Garnier | Neutral → Sell |
| Sep-08-20 | Initiated | SVB Leerink | Mkt Perform |
| Jun-25-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-23-20 | Initiated | Credit Suisse | Outperform |
| Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Dec-12-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Sep-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Sep-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | Morgan Stanley | Overweight |
| Aug-12-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Genmab Adr Stock (GMAB) Latest News
Grant of Restricted Stock Units and Warrants to Employees in Genmab - GlobeNewswire Inc.
10 Biggest Biotechnology Companies - Investopedia
Weekly Upgrades and Downgrades - InvestorPlace
Is the Options Market Predicting a Spike in Genmab (GMAB) Stock? - Yahoo Finance
Is Genmab (GMAB) Stock Undervalued Right Now? - Yahoo Finance
GMAB or INCY: Which Is the Better Value Stock Right Now? - Yahoo Finance
Down -14.68% in 4 Weeks, Here's Why Genmab (GMAB) Looks Ripe for a Turnaround - Yahoo Finance
Market Resilience: Genmab ADR (GMAB) Finishes Weak at 24.14, Down -5.44 - The Dwinnex
GANDHIM.APPL Share Price Today Up 13% - Equitymaster
Glenmark Pharma Share Price Today Down 3% - Equitymaster
Post-Trade Analysis: Genmab ADR (GMAB) Climbs 1.55, Closing at 26.90 - The Dwinnex
Market Recap: Genmab ADR (GMAB)’s Negative Momentum, Closing at 27.41 - The Dwinnex
All You Need to Know About Genmab (GMAB) Rating Upgrade to Strong Buy - MSN
BioNTech's Loss Quadruples as COVID-19 Vaccine Demand Falls - Yahoo Finance
Wall Street Analysts Think Genmab (GMAB) Could Surge 45.08%: Read This Before Placing a Bet - Yahoo Finance
GMAB vs. CSLLY: Which Stock Is the Better Value Option? - Yahoo Finance
GMAB’s Stock Journey: What Investors Need to Know About Genmab ADR’s Performance - The InvestChronicle
Wall Street Analysts Believe Genmab (GMAB) Could Rally 52.33%: Here's is How to Trade - Zacks Investment Research
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024 - GlobeNewswire Inc.
ISS suggest Enhabit shareholders elect three AREX Capital nominees to board By Reuters - Investing.com
Antibody Drug Conjugates Market Insights 2018-2023 and - GlobeNewswire Inc.
AbbVie (ABBV) Up 24% in a Year: Buy, Sell or Hold the Stock? - Zacks Investment Research
GMAB or TECH: Which Is the Better Value Stock Right Now? - Yahoo Finance
GMAB vs. TECH: Which Stock Is the Better Value Option? - Yahoo Finance
PBYI vs. GMAB: Which Stock Should Value Investors Buy Now? - Yahoo Canada Shine On
Zacks.com featured highlights include Tap Genmab, KnowBe4, UserTesting, Enphase Energy and Gartner - Yahoo Lifestyle UK
Genmab (GMAB), AbbVie Lymphoma Candidate Gets Orphan Drug Tag - Yahoo Sport Australia
Zacks.com featured highlights Genmab, Hologic, ServiceNow and Splunk - Yahoo New Zealand News
Oncolytics Biotech Inc. (ONCY) Hit a 52 Week High, Can the Run Continue? - Yahoo New Zealand News
FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma - Yahoo Finance
AbbVie (ABBV) BLA for Epcoritamab Gets FDA Priority Tag - Yahoo New Zealand News
GILD or GMAB: Which Is the Better Value Stock Right Now? - Yahoo New Zealand News
Genmab A/S executes share buyback program - Investing.com India
Genmab advances share buy-back program - Investing.com India
Ratio Revelations: Genmab ADR (GMAB)'s Financial Metrics in the Spotlight – DWinneX - The Dwinnex
Truist Securities ups Genmab shares target By Investing.com - Investing.com
AbbVie (ABBV) Signs New Cancer/Immunology Deal With Frontier - Yahoo Lifestyle UK
Genmab ADR (GMAB)'s stock chart: A technical perspective – US Post News - US Post News
Genmab completes $1.8 billion acquisition of ProfoundBio By Investing.com - Investing.com
Is Genmab (GMAB) Outperforming Other Medical Stocks This Year? - Yahoo Lifestyle UK
500: Something went wrong - Investing.com
Earnings call: Genmab reports strong Q1 growth, plans ProfoundBio acquisition - Investing.com
GMAB: 3 Biotech Stocks Gaining Altitude and Interest - StockNews.com
Genmab's 'Evolution' Continues With A $1.8 Billion Deal; But Shares Slip - Investor's Business Daily
GMAB: Bank on the Future Returns With These 3 Biotech Stocks - StockNews.com
New Strong Buy Stocks for January 17th - Yahoo Finance
Genmab Adr Stock (GMAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):